The present study provided important insights into the management of EGFR-mutated NSCLC patients retreated with osimertinib, who had a significantly higher risk of ILD recurrence than those receiving other types of EGFR-TKI. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.